Clinical trials: Peripheral T-cell Lymphoma (PTCL)
- Condition Peripheral T-cell Lymphoma (PTCL)
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Hodgkin Disease, Peripheral T Cell Lymphoma
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
This trial will study brentuximab vedotin to find out whether it is an effective treatment for Hodgkin lymphoma (HL) and peripheral T-cell lymphoma (PTCL).
- Trial name
- NCT01716806
- Testing
- brentuximab vedotin, bendamustine, dacarbazine
- Where
- 54 sites in United States, Canada
- Volunteers
- 131 people
- Sponsor
- Seagen Inc.
Epstein-Barr Virus Associated Lymphoma, EBV-Positive DLBCL, NOS
An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas
A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas
- Conditions
- Epstein-Barr Virus Associated Lymphoma, EBV-Positive DLBCL, NOS, EBV-Related Non-Hodgkin Lymphoma, EBV Related PTCL, NOS
- Trial name
- NAVAL-1 (NCT05011058)
- Testing
- Nanatinostat in combination with valganciclovir
- Where
- 62 sites in United States, Australia and 12 more
- Volunteers
- 102 people
- Sponsor
- Viracta Therapeutics, Inc.
Peripheral T-cell Lymphoma
A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
This is a multi-center, parallel cohort, open-label, Phase 2 study of duvelisib, an oral dual inhibitor of phosphoinositide-3-kinase-delta, gamma (PI3K-δ,γ), in participants with relapsed/refractory peripheral T-cell lymphoma…
- Trial name
- PRIMO (NCT03372057)
- Testing
- Duvelisib
- Where
- 36 sites in United States, Germany and 3 more
- Volunteers
- 156 people
- Sponsor
- SecuraBio
Relapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma
Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies
This study is for patients with lymphoproliferative malignancies that have progressed after receiving a previous treatment (relapsed) or are no longer responding to treatment (refractory).
- Conditions
- Relapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma, Peripheral T-cell Lymphoma, B-cell Lymphoma
- Trial name
- NCT00481871
- Testing
- Pralatrexate Injection, Gemcitabine Hydrochloride, Vitamin B12
- Where
- 15 sites in United States
- Volunteers
- 119 people
- Sponsor
- Acrotech Biopharma Inc.
Peripheral T-Cell Lymphoma
A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
This study is a phase 2 multinational, multicenter, single-arm, open-label, non-randomized study to evaluate the efficacy and safety of SP-02L monotherapy in relapsed or refractory patients with peripheral T-cell lymphoma.
- Trial name
- NCT02653976
- Testing
- SP-02L (darinaparsin for injection)
- Where
- 24 sites in Hong Kong, Japan and 2 more
- Volunteers
- 67 people
- Sponsor
- Solasia Pharma K.K.
Peripheral T-Cell Lymphoma (PTCL)
Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, efficacy, and pharmacokinetics of HBI-8000 40 mg BIW in patients with relapsed or refractory PTCL (R/R PTCL).
- Trial name
- NCT02953652
- Testing
- HBI-8000
- Where
- 23 sites in Japan, South Korea
- Volunteers
- 55 people
- Sponsor
- HUYABIO International, LLC.
Lymphoma, T-cell, Peripheral
A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)
The purpose of the study was to assess efficacy, tolerability, safety and pharmacokinetics of Romidepsin in subjects with progressive or relapsed peripheral T-cell lymphoma
- Trial name
- NCT01456039
- Testing
- Romidepsin
- Where
- 17 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Celgene
Hematologic Malignancies, Solid Tumor
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Multicenter, open-label, phase 1a/1b trial of PF-07901800 (TTI-621) in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.
- Trial name
- NCT02663518
- Testing
- PF-0791800 (TTI-621), PF-07901800 (TTI-621) plus Rituximab, PF-07901800 (TTI-621) plus Nivolumab
- Where
- 51 sites in United States, Canada
- Volunteers
- 249 people
- Sponsor
- Pfizer
Lymphoma
A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)
This study will use a combination of Brentuximab vedotin with CHP to treat adult Chinese participants with CD30+ PTCL. The main aims of the study are to evaluate: Side effect from the A+CHP Check how much A+CHP stays in their…
- Trial name
- NCT05673785
- Testing
- Brentuximab Vedotin, Cyclophosphamide, Doxorubicin
- Where
- 16 sites in China
- Volunteers
- 52 people
- Sponsor
- Takeda
Peripheral T-cell Lymphoma
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
This clinical trial will study brentuximab vedotin with CHP to find out if the drugs work for people who have certain types of peripheral T-cell lymphoma (PTCL).
- Trial name
- NCT04569032
- Testing
- brentuximab vedotin, cyclophosphamide, doxorubicin
- Where
- 63 sites in United States, France and 3 more
- Volunteers
- 82 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma
Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL
AFM13-203 is a phase 2, open-label, multi-center, multi-cohort study with a safety run-in followed by expansion cohorts. The study is evaluating the safety and efficacy of AFM13 in combination with AB-101 in subjects with R/R…
- Trial name
- LuminICE-203 (NCT05883449)
- Testing
- AFM13, AB-101, Cyclophosphamide
- Where
- 15 sites in United States
- Volunteers
- 25 people
- Sponsor
- Affimed GmbH
Relapsed or Refractory Peripheral T Cell Lymphoma
Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)
This is a multinational, non-randomized, open-label, Phase 1/2 clinical study to evaluate the safety, tolerability and anti-tumor efficacy of AZD4205 as monotherapy in patients with peripheral T cell lymphoma (PTCL), who have…
- Trial name
- NCT04105010
- Testing
- golidocitinib
- Where
- 50 sites in United States, Australia and 2 more
- Volunteers
- 171 people
- Sponsor
- Dizal Pharmaceuticals
Hodgkin Lymphoma, Peripheral T Cell Lymphoma
A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma
This study will look at whether brentuximab vedotin works and is safe in the re-treatment setting. To be in this study, patients must have already received brentuximab vedotin as treatment and have cancer that progressed (got…
- Conditions
- Hodgkin Lymphoma, Peripheral T Cell Lymphoma, Anaplastic Large Cell Lymphoma
- Trial name
- NCT03947255
- Testing
- brentuximab vedotin
- Where
- 19 sites in United States
- Volunteers
- 12 people
- Sponsor
- Seagen Inc.
Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Cutaneous
Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma
The purpose of this study is to evaluate the safety, PK and efficacy of RP6530, a dual PI3K delta/gamma inhibitor in patients with relapsed and refractory T-cell Lymphoma.
- Trial name
- NCT02567656
- Testing
- RP6530
- Where
- 8 sites in United States
- Volunteers
- 58 people
- Sponsor
- Rhizen Pharmaceuticals SA
Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma
Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001
This study will enroll subjects with either Peripheral T-Cell Lymphoma (PTCL) or Cutaneous T-Cell Lymphoma(CTCL),including mycosis fungoides (MF) and Sezary Syndrome (SS), who have relapsed after achieving a complete response in…
- Trial name
- NCT01226472
- Testing
- KW-0761
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Adult T-Cell Leukemia and Lymphoma (ATL), Adult Peripheral T-Cell Lymphoma (PTCL)
Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL
This is a Phase I label dose escalation study of KW-0761 in relapsed patients with CCR4 positive Adult T-Cell Leukemia-Lymphoma (ATL) and Peripheral T-Cell lymphoma (PTCL).
- Trial name
- NCT00355472
- Testing
- KW-0761
- Where
- Japan
- Volunteers
- 16 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Peripheral T Cell Lymphoma, PTCL
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
This was a multi-center, prospective, non-randomized, open-label, Phase 2 clinical study to evaluate the safety and efficacy of BGB-A317 in participants with relapsed or refractory mature T- and natural killer (NK)-cell…
- Conditions
- Peripheral T Cell Lymphoma, PTCL, Extranodal NK/T-cell Lymphoma, Extranodal NK/T-cell Lymphoma, Nasal Type
- Trial name
- NCT03493451
- Testing
- Tislelizumab
- Where
- 24 sites in Canada, China and 3 more
- Volunteers
- 77 people
- Sponsor
- BeiGene
Refractory Peripheral T-Cell Lymphoma, Relapsed T-Cell Lymphoma
A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL
This is a single arm, open-label, multi-center study designed to demonstrate the efficacy and safety of pralatrexate when administered concurrently with vitamin B12 and folic acid supplementation to patients with relapsed or…
- Trial name
- NCT03349333
- Testing
- pralatrexate, Vitamin B12 and folic acid
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Mundipharma (China) Pharmaceutical Co. Ltd
Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL)
Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma
This is a single-arm, multi-center, open-label phase 2 study of the SINE™ compound selinexor given orally to patients with relapsed or refractory PTCL or CTCL.
- Trial name
- NCT02314247
- Testing
- Selinexor
- Where
- 5 sites in Australia, Singapore
- Volunteers
- 16 people
- Sponsor
- Karyopharm Therapeutics Inc
Relapsed or Refractory Peripheral T-Cell Lymphoma
Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy
Phase II study designed to investigate antitumor activity in terms of objective response rate (ORR) of tipifarnib subjects with advanced Peripheral T-Cell Lymphoma (PTCL).
- Trial name
- PTCL (NCT02464228)
- Testing
- Tipifarnib
- Where
- 13 sites in United States, South Korea and 1 more
- Volunteers
- 65 people
- Sponsor
- Kura Oncology, Inc.